118 related articles for article (PubMed ID: 19574781)
1. A 14-year-old female patient with FIGO stage IB endometrial carcinoma: a case report.
Mitamura T; Watari H; Todo Y; Koshida T; Sakuragi N
Int J Gynecol Cancer; 2009 Jul; 19(5):896-7. PubMed ID: 19574781
[TBL] [Abstract][Full Text] [Related]
2. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
3. [Possibility of PTEN expression on predicting pathologic risk factors of endometrioid adenocarcinoma before operation].
Lou HY; Lin kQ; Ye DF; Xie X; Yu X
Ai Zheng; 2005 Jun; 24(6):748-50. PubMed ID: 15946494
[TBL] [Abstract][Full Text] [Related]
4. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
5. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
6. Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Müllerian duct lineage: a case report.
Yano M; Shintani D; Katoh T; Hamada M; Ito K; Kozawa E; Hasegawa K; Yasuda M
Diagn Pathol; 2019 Jun; 14(1):54. PubMed ID: 31174566
[TBL] [Abstract][Full Text] [Related]
7. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
Bonfitto VL; de Angelo Andrade LA
Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
[TBL] [Abstract][Full Text] [Related]
8. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
9. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
10. Sertoliform endometrioid carcinoma of the endometrium with dual immunophenotypes for epithelial membrane antigen and inhibin alpha: case report and literature review.
Liang SX; Patel K; Pearl M; Liu J; Zheng W; Tornos C
Int J Gynecol Pathol; 2007 Jul; 26(3):291-7. PubMed ID: 17581414
[TBL] [Abstract][Full Text] [Related]
11. Endometrial carcinoma in a 15-year-old obese patient with persistent uterine bleeding.
Liu G; Wang Y; Zhang X; Yuan B; Han C; Xue F
Gynecol Endocrinol; 2014 Apr; 30(4):277-9. PubMed ID: 24456540
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of endometrioid adenocarcinoma in atypical polypoid adenomyoma.
Sonoyama A; Kanda M; Ojima Y; Kizaki T; Ohara N
Kobe J Med Sci; 2014 Dec; 60(3):E74-7. PubMed ID: 25612673
[TBL] [Abstract][Full Text] [Related]
14. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
15. Endometrioid adenocarcinoma treated by hysteroscopic endomyometrial resection.
Vilos GA; Ettler HC; Edris F; Hollett-Caines J; Abu-Rafea B
J Minim Invasive Gynecol; 2007; 14(1):119-22. PubMed ID: 17218243
[TBL] [Abstract][Full Text] [Related]
16. Endometrioid adenocarcinoma after insertion of a levonorgestrel-releasing intrauterine system.
Flemming R; Sathiyathasan S; Jackson A
J Minim Invasive Gynecol; 2008; 15(6):771-3. PubMed ID: 18971148
[TBL] [Abstract][Full Text] [Related]
17. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
18. The relationship between expression of p53/bcl-2 and clinicopathological criteria in endometrioid adenocarcinomas of the endometrium.
Sari I; Gocmen A; Bitiren M; Cakmak EA
Eur J Gynaecol Oncol; 2004; 25(1):79-80. PubMed ID: 15053067
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
